Today: 29 April 2026
Ucore Rare Metals stock dives nearly 15% into weekend as rare-earth pricing talks loom
1 February 2026
1 min read

Ucore Rare Metals stock dives nearly 15% into weekend as rare-earth pricing talks loom

Toronto, Feb 1, 2026, 12:53 EST — Market closed.

  • On Friday, Ucore Rare Metals dropped 14.6% on the TSX Venture Exchange
  • U.S. officials are set to hold allied discussions on stabilizing rare-earth prices next week
  • Traders are watching for updates following the Jan. 31 debt and warrant deadlines highlighted in earlier disclosures

Ucore Rare Metals fell 14.6% Friday, closing at C$8.36 on the TSX Venture Exchange. The stock had gained early, hitting C$9.50 before sliding to a session low of C$8.28.

The move matters because Washington is once again exploring ways to stabilize rare-earth prices — a factor that can make or break financing plans for smaller miners and potential processors. U.S. Under Secretary of State for Economic Affairs Jacob Helberg said officials plan to push for an agreement with allies on a pricing mechanism during next week’s meetings in Washington, describing it as an effort to “ensure price stability” for refiners and extractors. Bloomberg.com

Rare earths, essential in permanent magnets, electronics, and defense systems, often see volatile price swings. Numerous Western projects remain in the testing phase, struggling to compete with cheaper sources.

Friday’s decline marked the end of a volatile week for Ucore, which hit a peak of C$10.29 on Jan. 26 before retreating in the last days of the month, according to Yahoo Finance data.

On Friday, Ucore’s UURAF shares closed at $6.13 in U.S. over-the-counter trading, after swinging between $7.17 and $6.10, Yahoo Finance reports.

Ucore hasn’t updated its website with any new press releases since Jan. 15, so investors are left to watch sector news and adjust their positions heading into February.

Some investors are eyeing end-of-January deadlines noted in earlier filings. Ucore previously indicated certain convertible debentures mature on Jan. 31, 2026. The company also revealed warrants tied to revised debt deals that expire that same day.

The company announced plans for a rare-earth processing plant in Louisiana, employing its RapidSX separation technology. It frames the project as a move to boost non-China processing capacity.

Still, plenty can derail the process. Setting up any cross-border “pricing mechanism” might take longer than expected, face political pushback, or hit budget constraints. For early-stage firms, those delays are costly—they need capital and clear agreements with customers and governments to move forward.

On Monday (Feb. 2), eyes will be on Ucore to see if it steadies after Friday’s drop, with traders also looking out for updates on the late-January debt and warrant deadlines. Washington’s allied talks on rare-earth pricing could add to the news flow.

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 2:59 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Caterpillar stock price: 3 signals to watch before Monday’s open
Previous Story

Caterpillar stock price: 3 signals to watch before Monday’s open

Microsoft slump sets up a big week for Big Tech stock prices as Alphabet and Amazon report
Next Story

Microsoft slump sets up a big week for Big Tech stock prices as Alphabet and Amazon report

Go toTop